All In Biotech

Drug Trial Radar · NCT00081159

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

A Randomized Phase II Study Of Bone-Targeted Therapy In Advanced Androgen-Dependent Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Nov 10, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

80

Actual

Start

Jul 2004

Primary completion

Sep 2014

Study completion Sep 2014

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Apr 8, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin and leuprolide may fight prostate cancer by stopping the adrenal glands from producing androgens. Drugs used in chemotherapy such as doxorubicin work in different ways to stop tumor cells from dividing so they stop growing or die. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer. It is not yet known whether hormone (androgen) ablation therapy and chemotherapy combined with zoledronate is more effective with or without strontium-89 in treating prostate cancer and bone metastases. PURPOSE: This randomized phase II trial is studying giving hormone ablation therapy, doxorubicin, and zoledronate together with strontium-89 to see how well it works compared to hormone ablation therapy, doxorubicin, and zoledronate alone in treating patients with androgen-dependent prostate cancer and bone metastases.

Conditions

  • Metastatic Cancer
  • Prostate Cancer

Interventions

  • Doxorubicin hydrochlorideDrug

    Doxorubicin 20 mg/m\^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.

  • Goserelin acetateDrug

  • Leuprolide acetateDrug

  • Zoledronic acidDrug

    4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.

  • orchiectomyProcedure

  • strontium chloride SrRadiation

    1 dose of strontium-89 (4 millicurie (mCi) total dose) administered intravenously on the first day of treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to 90 months with evaulation in 4 week intervals for up to 6 months of treatment, then follow up until disease progression

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • M.D. Anderson Cancer Center at Orlando

    Orlando, Florida

  • CCOP - Wichita

    Wichita, Kansas

  • M.D. Anderson Cancer Center at University of Texas

    Houston, Texas

  • CCOP - Marshfield Clinic Research Foundation

    Marshfield, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.